Cancer Therapy-induced Dermatotoxicity as a Window to Understanding Skin Immunity

Area of Science:

• Oncology
• Dermatology
• Immunology

Background:

• Targeted molecular therapies and immunotherapies are common cancer treatments.
• Dermatotoxicity, including rash and pruritus, is a frequent adverse event in patients undergoing these therapies.
• These therapies can disrupt molecular pathways vital for maintaining skin immune homeostasis.

Purpose of the Study:

• To review emerging mechanistic insights into cancer therapy-induced dermatotoxicity.
• To highlight the connection between cutaneous adverse events and skin immunity.
• To identify knowledge gaps for future research in this field.

Main Methods:

• Literature review of recent studies on cancer therapy-induced dermatotoxicity.
• Analysis of molecular mechanisms underlying skin immune homeostasis.
• Synthesis of findings on cutaneous adverse events from targeted therapies and immunotherapies.

Main Results:

• Cancer therapies significantly impact skin immunity.
• Understanding dermatotoxicity mechanisms enhances knowledge of skin biology.
• Various targeted agents and immunotherapies share common pathways affecting the skin.

Conclusions:

• Cancer therapy-induced dermatotoxicity provides valuable models for studying skin immunity.
• Further research is needed to elucidate remaining knowledge gaps.
• This understanding can lead to better management of side effects and improved cancer treatment strategies.